EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Effectiveness of treatment for concussion-related convergence insufficiency: The CONCUSS study protocol for a randomized clinical trial

Tara L Alvarez, Mitchell Scheiman, Suril Gohel, Farzin Hajebrahimi iD, Melissa Noble, Ayushi Sangoi iD, Chang Yaramothu iD, Christina L Master, Arlene Goodman

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0314027 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Tara L Alvarez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, New Jersey, United States of America. Hauptthemen laut MEDLINE: Brain Concussion, Ocular Motility Disorders, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, National Eye Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To describe CONCUSS, a randomized clinical trial (RCT) designed to compare the following: the effectiveness of immediate office-based vergence/accommodative therapy with movement (OBVAM) to delayed OBVAM as treatments for concussion-related convergence insufficiency (CONC-CI) to understand the impact of time (watchful waiting), the effect of OBVAM dosage (12 versus 16 therapy sessions), and to investigate the underlying neuro-mechanisms of OBVAM on CONC-CI participants.

Methods

CONCUSS is an RCT indexed on https://clinicaltrials.gov/study/NCT05262361 enrolling 100 participants aged 11–25 years with medically diagnosed concussion, persistent post-concussive symptoms 4–24 weeks post-injury, and symptomatic convergence insufficiency. Participants will receive standard concussion care and will be randomized to either immediate OBVAM or delayed (by six weeks) OBVAM. At the Outcome 1 examination (week 7), clinical assessments of success as determined by changes in the near point of convergence (NPC), positive fusional vergence (PFV), and symptoms will be compared between the two treatment groups. After the Outcome 1 visit, those in the delayed group receive 16 visits of OBVAM, while those in the immediate OBVAM group receive four more therapy visits. Outcome 2 assessment will be used to compare both groups after participants receive 16 sessions of OBVAM. The primary measure is the between-group differences of the composite change in the NPC and PFV at the Outcome 1 visit. Secondary outcome measures include individual clinical measures, objective eye-tracking parameters, and functional brain imaging.

Conclusions

Major features of the study design include formal definitions of conditions and outcomes, standardized diagnostic and treatment protocols, a delayed treatment arm, masked outcome examinations, and the incorporation of objective eye movement recording and brain imaging as outcome measures. CONCUSS will establish best practices in the clinical care of CONC-CI. The objective eye movement and brain imaging, correlated with the clinical signs and symptoms, will determine the neuro-mechanisms of OBVAM on CONC-CI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain ConcussionOcular Motility DisordersRandomized Controlled Trials as TopicAdolescentAdultChildFemaleHumansMaleYoung AdultAccommodation, OcularConvergence, OcularPost-Concussion SyndromeTreatment Outcome

Autor:innen und Institutionen

  • Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, New Jersey, United States of America.
  • Pennsylvania College of Optometry, Salus University, Philadelphia, Pennsylvania, United States of America.
  • Department of Health Informatics, Rutgers University School of Health Professions, Newark, New Jersey, United States of America.
  • School of Applied Engineering and Technology, New Jersey Institute of Technology, Newark, New Jersey, United States of America.
  • Sports Medicine and Performance Center, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.
  • Somerset Pediatric Group, Raritan, New Jersey, United States of America.

ORCID-Profile: Farzin Hajebrahimi, Ayushi Sangoi, Chang Yaramothu

Förderung

  • NEI NIH HHS
  • National Eye Institute

Zitieren

APA

Alvarez, T. L., Scheiman, M., Gohel, S., Hajebrahimi, F., Noble, M., Sangoi, A., Yaramothu, C., Master, C. L., & Goodman, A. (2024). Effectiveness of treatment for concussion-related convergence insufficiency: The CONCUSS study protocol for a randomized clinical trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0314027

Vancouver

Alvarez TL, Scheiman M, Gohel S, Hajebrahimi F, Noble M, Sangoi A, et al. Effectiveness of treatment for concussion-related convergence insufficiency: The CONCUSS study protocol for a randomized clinical trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0314027

BibTeX
@article{Alvarez2024,
  author = {Alvarez, Tara L and Scheiman, Mitchell and Gohel, Suril and Hajebrahimi, Farzin and Noble, Melissa and Sangoi, Ayushi and Yaramothu, Chang and Master, Christina L and Goodman, Arlene},
  title = {Effectiveness of treatment for concussion-related convergence insufficiency: The CONCUSS study protocol for a randomized clinical trial},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0314027}
}
Kostenlos starten →